Article Text

This article has corrections. Please see:

other Versions

PDF
Treating rheumatoid arthritis to target: recommendations of an international task force
  1. Josef S Smolen1,2,
  2. Daniel Aletaha1,
  3. Johannes W J Bijlsma3,
  4. Ferdinand C Breedveld4,
  5. Dimitrios Boumpas5,
  6. Gerd Burmester6,
  7. Bernard Combe7,
  8. Maurizio Cutolo8,
  9. Maarten de Wit9,
  10. Maxime Dougados10,
  11. Paul Emery11,
  12. Alan Gibofsky12,
  13. Juan Jesus Gomez-Reino13,
  14. Boulos Haraoui14,
  15. Joachim Kalden15,
  16. Edward C Keystone16,
  17. Tore K Kvien17,
  18. Iain McInnes18,
  19. Emilio Martin-Mola19,
  20. Carlomaurizio Montecucco20,
  21. Monika Schoels2,
  22. Desirée van der Heijde4
  1. 1Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
  2. 22nd Department of Medicine, Center for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria
  3. 3University Medical Center Utrecht, Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands
  4. 4Leiden University Medical Center, Department of Rheumatology, Leiden, The Netherlands
  5. 5Department of Medicine, Faculty of Medicine, University of Crete, Crete, Greece
  6. 6Humboldt University, Department of Rheumatology and Clinical Immunology, Charite Hospital, Berlin, Germany
  7. 7Service d’Immuno-Rhumatologie, Montpellier University, Lapeyronie Hospital, Montpellier, France
  8. 8Research Laboratory and Academic Clinical Unit of Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy
  9. 9EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland
  10. 10René Descartes University, Cochin Hospital, Department of Rheumatology B, Paris, France
  11. 11Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, UK
  12. 12Weill Medical College, Cornell University Hospital for Special Surgery, New York, USA
  13. 13Santiago University Clinical Hospital, NEIRID Laboratory, Santiago de Compostela, Spain
  14. 14Institut de rhumatologie de Montréal, Montréal, QC, Canada
  15. 15Fiebiger Center, Friedrich-Alexander University, Erlangen, Germany
  16. 16University of Toronto, Toronto, Canada
  17. 17Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  18. 18University of Glasgow, Glasgow, UK
  19. 19La Paz Hospital, Madrid, Spain
  20. 20Department of Rheumatology, University of Pavia, IRCCS Policlinico S Matteo, Pavia, Italy
  1. Correspondence to Dr Josef S Smolen, Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna,Waehringer Guertel 18-20, A-1090 Vienna, Austria; josef.smolen{at}wienkav.at

Abstract

Background Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA).

Objective To develop recommendations for achieving optimal therapeutic outcomes in RA.

Methods A task force of rheumatologists and a patient developed a set of recommendations on the basis of evidence derived from a systematic literature review and expert opinion; these were subsequently discussed, amended and voted upon by >60 experts from various regions of the world in a Delphi-like procedure. Levels of evidence, strength of recommendations and levels of agreement were derived.

Results The treat-to-target activity resulted in 10 recommendations. The treatment aim was defined as remission with low disease activity being an alternative goal in patients with long-standing disease. Regular follow-up (every 1–3 months during active disease) with appropriate therapeutic adaptation to reach the desired state within 3 to a maximum of 6 months was recommended. Follow-up examinations ought to employ composite measures of disease activity which include joint counts. Additional items provide further details for particular aspects of the disease. Levels of agreement were very high for many of these recommendations (≥9/10).

Conclusion The 10 recommendations are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA based on evidence and expert opinion.

Statistics from Altmetric.com

Footnotes

  • For numbered affiliations see end of article

  • Additional members of the T2T Expert Committee Jose Louis Andreu (Spain), Martin Bergman (USA), Harald Burkhardt (Germany), Vivian Bykerk (Canada), Mario Cardiel (Mexico), Filip Codruta (Romania), Hector Corominas (Spain), Alexandros Drosos (Greece), Patrick Durez (Belgium), Hani ElGabalawy (Canada), Cristina Estrach (UK), Bruno Fautrel (France), Gianfranco Ferracioli (Italy), Roy Fleischman (USA), Joao Eurico Fonseca (Portugal), Cem Gabay (Switzerland), Clara Gjesdal (Norway), Laure Gossec (France), Winfried Graninger (Austria), Espen Haavardsholm (Norway), Sesilie Halland (Norway), Pekka Hannonen (Finland), Jamie Henderson (Canada), Jonathan Kay (USA), Wenche Koldingsnes (Norway), Marios Kouloumas (Cyprus), Ieda Maria Laurindo (Brazil), Marjatta Leirisalo-Repo (Finland), Carlomaurizio Montecucco (Italy), Peter Nash (Australia), Mikkel Ostergaard (Denmark), Andrew Ostor (UK), Karel Pavelka (Czech Republic), José Peirera da Silva (Portugal), Kim Horslev Peterson (Denmark), Duncan Porter (UK), Enid Quest (UK), Evangelos Romas (Australia), Marieke Scholte (The Netherlands), Luigi Sinigaglia (Italy), Tuulikki Sokka (Finland), Ewa Stanislawska (Poland), Tsutomu Takeuchi (Japan), Guillermo Tate (Argentina), Athanasios Tzioufas (Greece), Peter Villiger (Switzerland).

  • Competing interests This work was supported by an unrestricted educational grant from Abbott Immunology. Abbott affiliates were not involved in the programme or any voting. At the end of the voting process, the Expert Committee was asked to vote in an anonymous fashion if they felt they had been influenced by the sponsoring of the event by Abbott. This ballot resulted in an agreement of 8.7/10 that they did not consider that the fact that Abbott was sponsoring this programme created a bias. The handling editor was F Berenbaum.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Miscellaneous
    BMJ Publishing Group Ltd and European League Against Rheumatism
  • Miscellaneous
    BMJ Publishing Group Ltd and European League Against Rheumatism